Loci Orthopaedics Earns New Patent for Thumb Base Joint Implant System

Loci Orthopaedics has been awarded a new patent for the bespoke implantation set for its InDx CMC Implant System.
 
In addition to the recently granted patent, other granted patents include the core design of its implant technology (US 10,265,186), the use of the same biomechanical design in additional joints (US 11,213,401), discrete elements of the implant design (US 10,799,365), and the use of the design post trapeziectomy (US 11,399,950).
 
Furthermore, the company recently received notification from the USPTO of its intention to grant a patent for the conversion of the design from a hemi-arthroplasty to a total arthroplasty. In total, the company has now been granted six individual patents for its implant system to treat thumb base joint arthritis. This makes Loci Orthopaedics the holder of one of the largest CMC joint implant patent portfolios.
 
Over 30 million people in the EU and 20 million people in the U.S. are affected by this condition. It is estimated that the current market potential is over €700 million per year, with this predicted to grow to over $1 billion in the next 5 years.
 
Loci Orthopaedics was recently granted over $8 million from the European Union government to advance and accelerate the development of the InDx Implant, reflecting the major unmet clinical need and significant market opportunity.
 
CEO and co-founder of Loci Orthopaedics, Brendan Boland, commented, “The company focuses on evidence-based design and providing unique design solutions for customers and patients. This is reflected in the company’s rapidly growing patent portfolio. The company now holds one of the most significant IP portfolios of implant designs for the thumb base joint.”
 
CTO and co-founder of Loci Orthopaedics, Gerry Clarke, added, “The company has granted patents not only for a novel and exciting treatment option for this condition, but also for the bespoke tool set to facilitate the optimal implantation. In addition, the company has granted patents for several different stages of this common and debilitating condition, opening a whole new potential treatment option spectrum.”